Nasir Khan，兽医学博士、博士：临床前开发高级副总裁Gary Ingenito，医学博士、博士：临床开发高级副总裁 沃尔瑟姆，马萨诸塞州, Oct. 22, 2025 (GLOBE NEWSWIRE) -- 维泰瑞隆是一家处于临床阶段的全球化生物科技公司，致力于探索和开发用于治疗衰老相关疾病的变革性疗法。公司今日宣布任命Nasir Khan，兽医学博士、博士，为临床前开发高级副总裁，任命自2025年10月20日起生效；任命Gary Ingenito，医学博士、博士，为临床开发高级副总裁，任命自2025年11月1日起生效。两位将在公司位于马萨诸塞州沃尔瑟姆的行政总部工作，向维泰瑞隆总裁兼首席执行官Dr. Shefali Agarwal汇报。 Dr. Agarwal表示：“我们很高兴并欢迎两位杰出领导者的加入，这将帮助公司进一步壮大和推进我们的研发管线，其中包括三个临床阶段项目、四个有望成为同类首创或同类最佳的分子，以及若干早期临床前项目。Nasir Khan博士和Gary Ingenito博士在全球药物发现和开发领域拥有深厚的专业积累，并且推动了多个对患者具有重大意义的创新疗法的诞生。我们期待两位领导者 ...

Major Events - Zhonghui Biotech-B (02627) has its Huierkangxin® vaccine selected as the only vaccine in the preliminary list of innovative drugs for national medical insurance [1] - Stone Pharmaceutical Group (02005) has received approval from the National Medical Products Administration for the registration of Aminopyridine as an active pharmaceutical ingredient for marketed formulations [1] - Gilead Sciences-B (01672) reports that its obesity treatment candidate ASC47 shows better efficacy in preclinical models when combined with Teriparatide compared to Semaglutide [1] - GAC Group (02238) plans to increase investment of 600 million yuan in Huawang Automotive [1] - Tongguan Gold (00340) has been included in the MSCI Global Small Cap Index [1] Operating Performance - Tencent Holdings (00700) reported a net profit attributable to equity holders of 63.052 billion yuan for Q2, a year-on-year increase of 10% [1] - Cheung Kong Infrastructure Group (01038) announced a mid-year profit attributable to shareholders of 4.348 billion HKD, up 0.9% year-on-year [1] - Power Assets Holdings (00006) reported a mid-year profit attributable to shareholders of 3.042 billion HKD, an increase of 1.2% year-on-year [1] - Nexperia (01316) disclosed a mid-year profit attributable to equity holders of 63.48 million USD, a year-on-year increase of 304.46% [1] - Value Partners Group (00806) reported a mid-year profit attributable to shareholders of 252 million HKD, a significant increase of 572.7% year-on-year [1] - Samsonite (01910) announced a mid-year profit attributable to equity holders of 118 million USD, a year-on-year decrease of 30.2% [1] - Multi-Point Intelligence (02586) reported a mid-year profit attributable to shareholders of 67.526 million HKD, returning to profitability year-on-year [1] - Laika Pharmaceuticals-B (02105) has made significant clinical progress in its core pipeline in the first half of the year, with R&D expenses exceeding 100 million yuan [1] - China Metallurgical Group (01618) reported new contract signings of 611.34 billion yuan from January to July, a year-on-year decrease of 18.5% [1] - China Shenhua Energy (01088) reported coal sales of 24.27 million tons in the first seven months, a year-on-year decrease of 10.1% [1]

Core Viewpoint - The announcement highlights that Stone Four Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Amaprine to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the first company in the country to achieve this [1] Company Summary - Stone Four Pharmaceutical Group's Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]

石四药集团(02005)发布公告，集团的氨吡啶已获中国国家药品监督管理局批准登记成为在上市制剂使 用的原料药，是国内首家获批。氨吡啶是一种钾通道阻滞剂，主要用于改善某些多发性硬化症成年人步 行速度。 ...

智通财经APP讯，石四药集团(02005)发布公告，集团的氨吡啶已获中国国家药品监督管理局批准登记成 为在上市制剂使用的原料药，是国内首家获批。氨吡啶是一种钾通道阻滞剂，主要用于改善某些多发性 硬化症成年人步行速度。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的氨吡啶已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥，是國內 首家獲批。氨吡啶是一種鉀通道阻滯劑，主要用於改善某些多發性硬化症成年人步行速度。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年八月十三日 ...